Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Crit Care Med. 2010 Jun;38(6):1414-22. doi: 10.1097/CCM.0b013e3181de18bc.
The receptor for advanced glycation end products mediates a variety of inflammatory responses. Soluble receptor for advanced glycation end products has been suggested to function as a decoy abrogating cellular activation. High-mobility group box 1 is a high-affinity binding ligand for the receptor for advanced glycation end products with cytokine activities and plays a role in sepsis.
Controlled, in vivo laboratory study.
Research laboratory of a health sciences university.
C57BL/6 mice.
Peritonitis was induced by intraperitoneal injection of Escherichia coli. Mice received soluble receptor for advanced glycation end products or anti-high-mobility group box 1 immunoglobulin G, or the appropriate control treatment.
Soluble receptor for advanced glycation end products-treated mice demonstrated an enhanced bacterial dissemination to liver and lungs, accompanied by increased hepatocellular injury and exaggerated systemic cytokine release, 20 hrs after intraperitoneal administration of Escherichia coli. Soluble receptor for advanced glycation end products administration in healthy, uninfected mice did not induce an immune response. Remarkably, lung inflammation was unaffected. Furthermore, high-mobility group box 1 release was enhanced during peritonitis and anti-high-mobility group box 1 treatment was associated with higher bacterial loads in liver and lungs.
These data are the first to suggest that receptor for advanced glycation end products ligands, including high-mobility group box 1, limit bacterial dissemination during Gram-negative sepsis.
晚期糖基化终产物受体介导多种炎症反应。可溶性晚期糖基化终产物受体被认为可作为一种诱饵,阻断细胞激活。高迁移率族蛋白 B1 是晚期糖基化终产物受体的高亲和力结合配体,具有细胞因子活性,并在脓毒症中发挥作用。
体内对照实验室研究。
一所健康科学大学的研究实验室。
C57BL/6 小鼠。
通过腹腔内注射大肠杆菌诱导腹膜炎。小鼠接受可溶性晚期糖基化终产物受体或抗高迁移率族蛋白 B1 免疫球蛋白 G 治疗,或接受适当的对照治疗。
20 小时后,接受可溶性晚期糖基化终产物受体治疗的小鼠表现出细菌向肝脏和肺部扩散增强,伴有肝实质细胞损伤增加和全身细胞因子释放加剧,而腹腔内注射大肠杆菌后,接受可溶性晚期糖基化终产物受体治疗的健康、未感染的小鼠并未引发免疫反应。值得注意的是,肺部炎症不受影响。此外,高迁移率族蛋白 B1 在腹膜炎期间释放增加,而抗高迁移率族蛋白 B1 治疗与肝脏和肺部的更高细菌负荷相关。
这些数据首次表明,晚期糖基化终产物受体配体(包括高迁移率族蛋白 B1)可限制革兰氏阴性菌脓毒症期间的细菌播散。